Pharmaids Pharmaceuticals Ltd

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.

Pharmaids Pharmaceuticals Ltd’s shares declined sharply to a new 52-week low of Rs.30 today, marking a significant drop amid a challenging market environment. The stock underperformed its sector and broader indices, reflecting ongoing concerns about the company’s financial health and market position.

Pharmaids Pharmaceuticals Ltd has reached a new 52-week low of Rs.30.56, marking a significant decline in its stock price amid broader market gains. The stock underperformed its sector and continues to trade below all key moving averages, reflecting ongoing pressures within the company’s financial and operational metrics.

Pharmaids Pharmaceuticals Ltd has touched a new 52-week low of Rs.34 today, marking a significant decline in its stock price amid broader market volatility and company-specific performance concerns. This level represents a sharp drop from its 52-week high of Rs.75.98, reflecting a year-long downward trajectory for the pharmaceutical firm.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 28 May 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 19 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Pharmaids Pharmaceuticals Ltd has reached a new 52-week low of Rs.34.5 today, marking a significant decline amid broader market gains. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and market positioning.

Pharmaids Pharmaceuticals Ltd has touched a new 52-week low of Rs.35 today, marking a significant decline in its share price amid broader market gains. The stock underperformed its sector and the benchmark indices, reflecting ongoing concerns about the company’s financial health and market position.

Pharmaids Pharmaceuticals Ltd has reached a new 52-week low of Rs.35.2 today, marking a significant decline in its stock price amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock has underperformed both its sector and the broader market, reflecting persistent challenges in its financial performance and valuation metrics.

Pharmaids Pharmaceuticals Ltd has demonstrated a notable improvement in its financial performance for the quarter ended December 2025, signalling a positive shift from a previously flat trend. Despite this progress, the company continues to grapple with elevated interest expenses and a challenging operating environment, reflected in its current market valuation and stock performance.

Pharmaids Pharmaceuticals Ltd., a Hyderabad-based contract research and manufacturing services provider, reported a consolidated net loss of ₹2.48 crores in Q3 FY26 (October-December 2025), marking yet another quarter of persistent losses despite revenue improvements. The micro-cap pharmaceutical company, with a market capitalisation of ₹139.84 crores, continues to struggle with profitability as operating margins remain deeply negative at -46.04%. Following the results announcement, the stock traded at ₹39.65 on February 13, 2026, down 47.82% from its 52-week high of ₹75.98, reflecting investor concerns about the company's ability to achieve sustainable profitability.

Pharmaids Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 28 May 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 08 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Pharmaids Pharmaceuticals Ltd has reached a new 52-week low of Rs.40.5, marking a significant decline in its stock price amid ongoing financial pressures and subdued market performance. This fresh low reflects the challenges the company faces within the Pharmaceuticals & Biotechnology sector, as it continues to underperform relative to broader market indices.

Pharmaids Pharmaceuticals Ltd has declined to a fresh 52-week low of Rs.40.6, marking a significant downturn amid broader market volatility and sector underperformance. The stock has now recorded a three-day consecutive fall, accumulating an 8.17% loss over this period, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Pharmaids Pharmaceuticals Ltd has reached a new 52-week low, closing near Rs 41.1, marking a significant decline in its stock price amid ongoing financial pressures and subdued performance metrics.

Pharmaids Pharmaceuticals Ltd has reached a new 52-week low of Rs.41.17 today, marking a significant decline in its stock price amid a challenging market environment and subdued financial performance over the past year.